Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RM-001 for transfusion-dependent beta-thalassemia
ChiCTR2300069244Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Dec 2022
- Modality
- Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of γ-globin reactivated autologous hematopoietic stem cells in beta thalassemia, sponsored by Sun Yat-sen Memorial Hospital. Primary endpoints: Absolute neutrophil count, Platelet count and 6 more. Planned start Dec 2022; status: not yet recruiting.
02
Drugs
γ-globin reactivated autologous hematopoietic stem cells
03
Conditions
beta thalassemia
Beyond the preview
Go deeper on ChiCTR2300069244.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300069244.